MSB 3.83% $1.26 mesoblast limited

MSB looks cheap

  1. 5,481 Posts.
    lightbulb Created with Sketch. 8927
    Might sound silly, at 12 month highs- but given that all four tier 1 programs are all up for partnering and have passed recent hurdles (albeit low ones) the outlook is looking very bright.

    With the recent spate of failures in RA and CHF drugs from big pharmaceuticals (Lilly and Novartis respectively) the spot light is being shone on regenerative medicine.

    And the leader of the pack is non other than Mesoblast.

    We could see a partner for CHF sooner rather than later, with the recent successful futility test and Novartis failure likely to make it a highly sought after program for the likes of Astrzeneca, Pfizer, even Novartis or Lilly!

    Nasdaq seems to be picking up on the sentiment quicker than the ASX, but that is expected with the Nasdaq having a greater appreciation of the market that MSB is looking to crack into.
    Last edited by stockrock: 19/04/17
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.26
Change
-0.050(3.83%)
Mkt cap ! $1.432B
Open High Low Value Volume
$1.27 $1.30 $1.17 $21.32M 17.21M

Buyers (Bids)

No. Vol. Price($)
4 5460 $1.25
 

Sellers (Offers)

Price($) Vol. No.
$1.26 978 1
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.